title: Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report.
abstract: Interferon alpha (IFN-alpha) can be effective therapy for patients with chronic kidney disease who have chronic hepatitis C (HCV). However, acute allograft rejection has been reported in association with IFN-alpha following kidney transplantation, and therefore IFN therapy is recommended prior to, rather than after, kidney transplantation whenever feasible. The special case of repeat allograft recipients who contract HCV after the first transplantation presents special difficulties. This report features the case of a repeat allograft recipient who presented with neutropenic fevers after 5 months of pegylated IFN-alpha therapy, initiated 6 months following the functional loss of his third graft and the reinitiation of hemodialysis (HD). Physical exam, radiographic and laboratory findings led to allograft nephrectomy. The pathologic findings supported a diagnosis of acute-on-chronic rejection. This represents a rare case of IFN-alpha induced rejection following allograft failure and return to HD in a repeat allograft recipient. It also calls attention to the need for a high index of suspicion for the development of allograft rejection, which may require allograft nephrectomy even after allograft 'failure'.
authors.affiliation: Department of Medicine, Walter Reed Army Medical Center, Washington, DC, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Carbognin
authors.forename: N M
authors.initials: NM
authors.lastname: Solomon
authors.forename: F E
authors.initials: FE
authors.lastname: Yeo
authors.forename: S J
authors.initials: SJ
authors.lastname: Swanson
authors.forename: E M
authors.initials: EM
authors.lastname: Bohen
authors.forename: J M
authors.initials: JM
authors.lastname: Koff
authors.forename: S G
authors.initials: SG
authors.lastname: Sabnis
authors.forename: K C
authors.initials: KC
authors.lastname: Abbott
mesh_terms: D006084:Graft Rejection / Q000000981:diagnostic imaging / Q000473:pathology; D016174:Hepacivirus / Q000187:drug effects* / Q000502:physiology*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011859:Radiography; D011994:Recombinant Proteins; D006435:Renal Dialysis; D015898:Tomography Scanners, X-Ray Computed; D014184:Transplantation, Homologous
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b